darunavir

Darunavir belongs to a group of drugs known as protease inhibitors. Its primary function is to reduce the level of HIV in the bloodstream. While darunavir cannot completely eradicate HIV, it can lower the risk of developing acquired immunodeficiency syndrome (AIDS) and HIV-related conditions like severe infections or cancer.

Darunavir has the potential to cause severe and life-threatening side effects, such as liver complications and severe skin reactions or rashes.

Darunavir, also known by its brand name Prezista, is a medication that has been approved by the FDA for the treatment of HIV infection in both adults and children.

PREZISTA (darunavir) inhibits the protease of the human immunodeficiency virus (HIV-1).

A generic drug is a medication that contains the same active ingredient as a brand-name drug, but is usually sold under its chemical name rather than a brand name. Generic drugs are typically produced and sold after the patent for the brand-name drug has expired. They are equivalent in terms of safety, effectiveness, dosage form, strength, and route of administration to the brand-name drug.

Darunavir is mainly broken down by the liver’s cytochrome P450 (CYP) enzymes, particularly CYP3A. Ritonavir’s ‘boosting’ dose works by inhibiting CYP3A, which in turn increases the amount of darunavir that is available in the body.

The price of a 60-tablet supply of darunavir oral tablet 600 mg is approximately $1,933, but this may vary depending on the pharmacy you choose. Please note that the quoted prices are for customers paying in cash and may not be applicable with insurance plans.

Darunavir (TMC114) is a sulfonamide, nonpeptidic protease inhibitor (PI) that belongs to the second generation of PIs. It has a distinctive, flexible, 3-dimensional structure that enhances its effectiveness and reduces the likelihood of developing resistance. To ensure optimal pharmacokinetics, darunavir should be taken with a low dose of ritonavir and consumed with food.

Darunavir is effective against HIV-1 as it works by inhibiting the HIV protease enzyme. It does this by forming a complex with the enzyme, preventing it from cleaving the gag-pol polyproteins. As a result, immature and non-infectious viral particles are produced.

Darunavir/cobicistat is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS, and is sold under the brand names Prezcobix in the US and Rezolsta in the EU.

Darunavir received approval for use in the United States in June 2006 and in the European Union in February 2007.

The pregnancy category of Darunavir is C.

Darunavir is a medication that is taken orally.

Darunavir is a medication used in combination therapy for HIV infection in adults who have been previously treated. It is an HIV protease inhibitor that has the unique benefit of maintaining its effectiveness even when there are multiple protease mutations present. To enhance its absorption in the body, darunavir is taken alongside a low dose of ritonavir.

Darunavir and ritonavir are both inhibitors and substrates of CYP3A4, which can potentially cause pharmacological interactions with many drugs frequently prescribed to HIV-infected individuals.

Darunavir (DRV) is an antiretroviral medication that is commonly prescribed under the brand name Prezista to treat and prevent HIV/AIDS. It is typically used in combination with other antiretrovirals. To enhance the effectiveness of darunavir, it is often administered alongside low doses of ritonavir or cobicistat to elevate darunavir levels.

One of the drugs included in the combination therapy Biktarvy is known to cause weight gain. Weight gain is commonly associated with protease inhibitors such as atazanavir (Reyataz), darunavir (Prezista), and tipranavir (Aptivus). However, the newer group of HIV medications known as integrase strand transfer inhibitors (INSTIs) are the ones that are most likely to result in weight gain.

According to the official answer, there have been case reports of hair loss (alopecia) associated with the use of Biktarvy. However, the manufacturer’s clinical studies of Biktarvy did not mention hair loss as a side effect.

Recent research indicates that all integrase strand inhibitors, including bictegravir found in Biktary, may be associated with weight gain. Studies have shown that patients experienced a median weight gain of 1 kg (2.2 lbs) to 4 kg (8.8 lbs) over a period of one to two years. Additionally, some individuals have reported a weight gain of more than 10%.

Although weight gain or weight loss is not listed as a direct side effect of Humira (adalimumab) in the product labeling, it is possible that other factors such as underlying conditions, symptoms, or medications may impact your weight while taking this medication.

Darunavir is advantageous in that it maintains its virological activity even in the presence of multiple protease mutations. Its bioavailability is increased through coadministration with low-dose ritonavir.

During therapy with darunavir/ritonavir, the majority of reported side effects were mild. The most frequently observed side effects included diarrhea, nausea, vomiting, headache, rash, and abdominal pain.

Some of the serious side effects associated with Biktarvy include depression, liver damage, and immune reconstitution inflammatory syndrome (IRIS).

Biktarvy has the potential to induce depression, as evidenced by studies where individuals taking Biktarvy reported suicidal thoughts or made suicide attempts. However, it is important to note that the occurrence of depression in clinical studies was less than 2% among Biktarvy users.

The weight gain in the SYMTUZA group over 48 weeks ranged from 3.13 lbs (1.42 kg) to 3.84 lbs (1.75 kg) in 1,125 patients, while the control group experienced an average weight gain of approximately 1 lb (.45 kg) in 741 patients. It is important to note that the long-term effects of SYMTUZA on weight have not been investigated in clinical trials.

However, in the most recent version of the DHHS guidelines, atazanavir/ritonavir was reclassified as an ‘alternative’ to darunavir/ritonavir. This decision was made due to the high rates of discontinuation caused by toxicity among patients treated with atazanavir/ritonavir in ACTG 5257, a randomized trial that compared the effectiveness of atazanavir/ritonavir.

Input: Darunavir
Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
Emtricitabine / tenofovir alafenamide
Dosage Form(s) Available
Oral tablet
Oral tablet
Oral tablet
Brand Names
Prezista
N/A
Descovy

Output:
Darunavir is available in oral tablet form and is sold under the brand name Prezista.
Biktarvy is a combination medication containing bictegravir, emtricitabine, and tenofovir alafenamide. It is available in oral tablet form.
Emtricitabine / tenofovir alafenamide is available in oral tablet form and is sold under the brand name Descovy.

This drug may interact with products such as orlistat, certain seizure medications (carbamazepine, phenytoin, primidone), barbiturates (phenobarbital, secobarbital), and a specific combination HIV medication (elvitegravir/cobicistat/emtricitabine/tenofovir).

Darunavir is mainly broken down by the liver’s cytochrome P450 (CYP) enzymes, particularly CYP3A. Ritonavir’s ‘boosting’ dose works by inhibiting CYP3A, which in turn increases the amount of darunavir that is available in the body.

Do not take this medication if you have an allergy to ritonavir or any other medications. Individuals with liver issues, including hepatitis B or C, heart problems, diabetes, or high blood sugar should also avoid taking this medication.

Darunavir (DRV) is an antiretroviral medication that is commonly prescribed under the brand name Prezista to treat and prevent HIV/AIDS. It is typically used in combination with other antiretrovirals. To enhance the effectiveness of darunavir, it is often administered alongside low doses of ritonavir or cobicistat to elevate darunavir levels.

Darunavir, which is also referred to as darunavir ethanolate or DRV and sold under the brand name Prezista, is a medication that is utilized in antiretroviral therapy (ART).

If darunavir is taken without food, its drug levels decrease by 30%, which can result in inadequate control of HIV and an increased risk of developing resistance. To investigate the impact of different types of food on darunavir’s efficacy, a standard breakfast, a high-fat breakfast, a nutritional protein-rich drink, and a croissant with coffee were studied.

75% of people using darunavir reported a positive response, whereas 25% of people using darunavir reported a negative response.